Theraclion SA (EPA:ALTHE)
France · Delayed Price · Currency is EUR | Market Cap | 36.55M +229.2% |
| Revenue (ttm) | 652.00K -21.4% |
| Net Income | -5.69M |
| EPS | -0.10 |
| Shares Out | 73.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 211,507 |
| Average Volume | 184,892 |
| Open | 0.4965 |
| Previous Close | 0.5000 |
| Day's Range | 0.4850 - 0.5020 |
| 52-Week Range | 0.2760 - 1.2500 |
| Beta | 0.26 |
| RSI | 46.46 |
| Earnings Date | Apr 16, 2026 |
About Theraclion
Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient’s skin and optimize image quality. The company was incorporated in 2004 and is headquartered in Malakoff, France. [Read more]
Financial Performance
In 2025, Theraclion's revenue was 652,000, a decrease of -21.35% compared to the previous year's 829,000. Losses were -5.69 million, -1.16% less than in 2024.
Financial StatementsNews
Theraclion’s non-invasive varicose treatment poised for FDA decision
Theraclion said 2025 marked a “decisive year”, laying the groundwork for expansion as it prepares for a potential entry into the US market.